

# Quality Performance Indicators Audit Report



<b>Tumour Area:</b>	Endometrial Cancer
<b>Patients Diagnosed:</b>	1 <sup>st</sup> October 2019 – 30 <sup>th</sup> September 2020
<b>Published Date:</b>	8th February 2023

## 1. Patient Numbers and Case Ascertainment in the North of Scotland


Between 1<sup>st</sup> October 2019 and 30<sup>th</sup> September 2020, a total of 190 cases of endometrial cancer were diagnosed in the North of Scotland and recorded through audit. Overall case ascertainment was high at 94.9%, this suggests that patients with endometrial cancer are well captured by cancer audit in the North of Scotland. Furthermore, for patients included within the audit, data collection was near complete. As such, QPI calculations based on data captured are considered to be representative of patients diagnosed with endometrial cancer during the audit period.

**Case ascertainment and proportion of NoS total for patients diagnosed with endometrial cancer in 2019-2020**

	Grampian	Highland	Orkney	Shetland	Tayside	W Isles	NoS
<b>No. of Patients 2019-20</b>	89	38	3	0	57	3	<b>190</b>
<b>% of NoS total</b>	46.8%	20.0%	1.6%	0%	30.0%	1.6%	<b>100%</b>
<b>Mean ISD Cases 2014-18</b>	78.6	40.4	4	1.8	70.6	4.8	<b>200.2</b>
<b>% Case ascertainment 2019-20</b>	113.2%	94.1%	75.0%	0%	80.7%	62.5%	<b>94.9%</b>

## 2. Age Distribution

The figure below shows the age distribution of patients diagnosed with endometrial cancer in the North of Scotland in 2019-20, with numbers highest in the 65-69 years age bracket.



**Age distribution of patients diagnosed with endometrial cancer in the North of Scotland in 2019-2020.**

### **3. Performance against Quality Performance Indicators (QPIs)**

Definitions for the QPIs reported in this section are published by Health Improvement Scotland<sup>1</sup>, while further information on datasets and measurability used are available from Information Services Division<sup>2</sup>. Data for most QPIs are presented by Board of diagnosis; however QPI 4 and QPI 7 are presented by hospital of surgery. In addition, QPI 8, clinical trials and research study access, is reported by NHS Board of residence.

*\*Where the number of cases per Board is between one and four, results have been excluded from charts and tables to minimise the risk of disclosure. However, all board results are included within the total for the North of Scotland.*


### **4. Governance and Risk**

QPI performance is overseen by the North Cancer Alliance and its constituent groups, with an assessment of clinical risk and action planning undertaken collaboratively and reporting at board and regional level. Actions will be overseen by the Pathway Boards and reported concurrently into the NCA governance groups and the Clinical Governance committees at each North of Scotland health board.

Further information is available [here](#).


**QPI 1 Radiological Staging**

Proportion of patients with endometrial cancer who have an MRI and/or CT scan of the abdomen and pelvis performed prior to definitive treatment.




**QPI 2 Multidisciplinary Team Meeting (MDT)**

Proportion of patients with endometrial cancer who are discussed at a MDT meeting before definitive treatment.




**QPI 3**      **Total Hysterectomy and Bilateral Salpingo-Oophorectomy**

Proportion of patients with endometrial cancer who undergo TH/BSO.




**QPI 4**      **Laparoscopic Surgery**

Proportion of patients with endometrial cancer undergoing definitive surgery who undergo laparoscopic surgery.




<b>QPI 5</b>	<b>Adjuvant Radiotherapy</b>
Proportion of patients with stage IB, grade 1 or 2, or stage IA, grade 3 endometrioid or mucinous endometrial cancer having adjuvant radiotherapy.	




All patients who did not receive Adjuvant Radiotherapy have been audited by boards and reasons including patient fitness and patient choice provided as why they did not progress for adjuvant treatment.

<b>QPI 6</b>	<b>Systemic Anti Cancer Therapy (SACT) / Hormone Therapy</b>
Proportion of patients with stage IV endometrial cancer receiving SACT or hormone therapy.	




**QPI 7**      **30 Day Mortality Following Surgery**

Proportion of patients with endometrial cancer who die within 30 days of surgery for endometrial cancer.



**QPI 8**      **Clinical Trials and Research Study Access**

Proportion of patients diagnosed with endometrial cancer who are consented for a clinical trial / research study. Data reported are for patients consented in 2020.



## References

1. Scottish Cancer Taskforce, 2018. Endometrial Cancer Clinical Quality Performance Indicators, Version 3.0. Health Improvement Scotland.  
<http://www.healthcareimprovementscotland.org/his/idoc.ashx?docid=26746da3-4b91-4d94-9ae2-623122731560&version=-1>
2. <http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Audit/>

## Appendix 1: Clinical trials and research studies for patients with endometrial cancer open within the North of Scotland in 2020.

Trial	Principle Investigator	Patients consented into trial in 2020
GARNET	Leslie Samuel (Grampian)	Y